Compare · BDX vs SWAV
BDX vs SWAV
Side-by-side comparison of Becton Dickinson and Company (BDX) and Shockwave Medical Inc. (SWAV): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BDX and SWAV operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BDX is the larger of the two at $51.69B, about 10.9x SWAV ($4.73B).
- BDX has hit the wire 11 times in the past 4 weeks while SWAV has been quiet.
- BDX has more recent analyst coverage (25 ratings vs 21 for SWAV).
- Company
- Becton Dickinson and Company
- Shockwave Medical Inc.
- Price
- $190.22+0.23%
- $334.80-0.01%
- Market cap
- $51.69B
- $4.73B
- 1M return
- +14.36%
- -
- 1Y return
- -2.00%
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 2019
- News (4w)
- 11
- 0
- Recent ratings
- 25
- 21
Becton Dickinson and Company
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps, dedicated disposables, IV fluids, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products and systems; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for high-throughput single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. Becton, Dickinson and Company was founded in 1897 and is based in Franklin Lakes, New Jersey.
Shockwave Medical Inc.
ShockWave Medical, Inc., a medical device company, engages in developing and commercializing intravascular lithotripsy technology to treat calcified plaque in patients with peripheral vascular, coronary vascular, and heart valve diseases worldwide. The company offers M5 catheters for treating above-the-knee peripheral artery disease; C2 catheters for treating coronary artery disease; and S4 catheters for treating below-the-knee peripheral artery disease. It serves interventional cardiologists, vascular surgeons, and interventional radiologists through sales representatives and sales managers, and distributors. ShockWave Medical, Inc. was incorporated in 2009 and is headquartered in Santa Clara, California.
Latest BDX
- BD to Present at Wells Fargo 21st Annual Healthcare Conference
- EVP, Chief Revenue Officer Feld Michael covered exercise/tax liability with 1,049 shares, decreasing direct ownership by 5% to 19,885 units (SEC Form 4) (for withholding tax)
- BD Appoints Gary Sorsher as Chief Quality Officer; Jeff Silvestri to Retire
- Chairman, CEO and President Polen Thomas E Jr exercised 43,278 shares at a strike of $167.25, returned $7,238,310 worth of shares to the company (39,126 units at $185.00) and sold $768,120 worth of shares (4,152 units at $185.00) as part of a pre-agreed trading plan (SEC Form 4)
- EVP and President, EMEA Goette Roland sold $440,888 worth of shares (2,438 units at $180.84), decreasing direct ownership by 14% to 14,856 units (SEC Form 4)
- BD Accelerates Advanced Tissue Regeneration Strategy with Landmark PREVENT Trial
- SEC Form 4 filed by Director Huffines Robert Luther
- SEC Form 4 filed by Director Byington Carrie L
- SEC Form 10-Q filed by Becton Dickinson and Company
- Becton Dickinson and Company filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
Latest SWAV
- Sonder Capital Closes its Second Fund and Announces Participation from Major Healthcare Systems
- Pulse Biosciences, Inc. Appoints Maria Sainz to its Board of Directors
- Bruker Appoints Laura Francis to its Board of Directors
- Deborah Kilpatrick Joins Sonder Capital as its Newest Venture Partner
- SEC Form 15-12G filed by Shockwave Medical Inc.
- Francis Laura returned 4,784 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Moll Frederic H returned 287,521 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Papiernik Antoine returned 34,913 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Sainz Maria returned 5,328 shares to the company, closing all direct ownership in the company (SEC Form 4)
- SEC Form S-8 POS filed by Shockwave Medical Inc.